Francesc Xavier Bosch Jose
e-oncologia Director and scientific advisor
Dr Xavier Bosch holds a Medical Degree (University of Barcelona, 1972), a Master of Public Health (University of California-Los Angeles, 1978), a Medical Specialty in Internal Medicine and Clinical Oncology (Autonomous University of Barcelona, 1982), and a PhD (Autonomous University of Barcelona, 1991). In 2016, he was awarded Doctor Honoris Causa by the University of Barcelona.
He worked as epidemiologist in the International Agency for Research on Cancer (IARC, 1982-1993) and as Visiting Scientist in the National Cancer Institute (NCI, 2002). He served as Director of the Cancer Epidemiology Research Program on the Catalan Institute of Oncology (ICO, 1994-2015), and has collaborated with several public health agencies and scientific organizations such as the Pan American Health Organization (PAHO), the Program for Appropriate Technology in Health (PATH), or the European Research Organization on Genital Infection and Neoplasia (EUROGIN) among others.
His scientific career has focused on cancers associated to infectious agents, notably on cancer of the liver, the cervix, the genital tract and of the oral cavity and oropharynx. His research in the IARC was instrumental in demonstrating the causal role of Human Papilloma Virus (HPV) in cervical cancer, establishing the role of the environmental co-factors for carcinogenesis among HPV-positive women, and describing the international variation of HPV types in cervical cancer and some of its major variants. His studies have triggered both the first HPV vaccine clinical trials and the evaluation of HPV tests as screening tools.
He has also made relevant contributions to the field of Hepatitis B virus (HBV) and liver cancer, such as the assessment of the impact of childhood HBV vaccination in liver cancer prevention in the Gambia Hepatitis Intervention Study (GHIS), the quantification of HBV and HCV action in liver cirrhosis and liver cancer by PCR, or the study of the role of dietary exposition to aflatoxin in liver cancer.
He was an early adopter of molecular epidemiology as a new field, by using novel biological assays at DNA level to assess exposure to viral carcinogens. He also conducted studies on diet and colorectal cancer, and he coordinated a program of implementation and methodological research in cancer registration. He participated in relevant epidemiological studies in 35 countries worldwide (especially in Latin America, Africa and Asia), always devoted to the application of aetiological knowledge into the prevention of cancer.
As part of his educational activities, he served as co-Director of the HPV Information Center, a web-based resource led by ICO and IARC that compiles, processes and disseminates published information on HPV infection and HPV-related diseases for each of the 194 WHO member states, with the aim of accelerating the development and introduction of prevention strategies worldwide. He also coordinated the publication of several monograph series on HBV and HPV in the IARC, the Journal of the National Cancer Institute and the journal Vaccine.
Starting in September 2017, he is currently Senior Researcher in the Bellvitge Biomedical Research Institute (IDIBELL) and Director of e-Oncologia, a distance-learning platform started in 2004 with a network of almost 200 lecturers and tutors and over 1500 hours of educational content (44 courses), specially addressed to health professionals. He is also the scientific and project coordinator of HPV World, an international newsletter started in 2017 that synthesizes and updates the current scientific literature about HPV and associated diseases, covering topics such as screening, vaccination, and clinical practice.
He is a current board member of the International Papillomavirus Society (IPVS) and coordinated the organization of the next IPVS conference, which took place virtually in July 2020. Currently he is Professor at the Faculty of Health Sciences at the Open University of Catalonia (UOC). He is also member of the CIBERESP Group, a network of 51 research groups from different institutions and universities in Spain devoted to solving public health issues by identifying the determining factors of those issues and by assessing the effectiveness and efficiency of interventions.
Bosch FX, Robles C, Díaz M, Arbyn M, Baussano I, Clavel C, Ronco G, Dillner J, Lehtinen M, Petry K-U, Poljak M, Kjaer SK, Meijer CJLM, Garland SM, Salmerón J, Castellsagué X, Bruni L, de Sanjosé S, Cuzick J (2016) HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol 13: 119–132, doi: 10.1038/nrclinonc.2015.146
Bosch FX, de Sanjose S, Castellsague X (2011) The prospects of HPV vaccination in cervical cancer prevention: results of a new independent trial. Cancer Discov 1: 377–380, doi: 10.1158/2159-8290.CD-11-0229
Castellsagué X, Díaz M, Vaccarella S, de Sanjosé S, Muñoz N, Herrero R, Franceschi S, Meijer CJLM, Bosch FX (2011) Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. Lancet Oncol 12: 1023–1031, doi: 10.1016/S1470-2045(11)70223-6
de Sanjose S, Quint WG, Alemany L, (…) Bosch FX, Retrospective International Survey and HPV Time Trends Study Group (2010) Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 11: 1048–1056, doi: 10.1016/S1470-2045(10)70230-8
Castellsagué X, Díaz M, de Sanjosé S, Muñoz N, Herrero R, Franceschi S, Peeling RW, Ashley R, Smith JS, Snijders PJF, Meijer CJLM, Bosch FX, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group (2006) Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 98: 303–315, doi: 10.1093/jnci/djj067
Bosch FX, de Sanjosé S (2003) Chapter 1: Human papillomavirus and cervical cancer--burden and assessment of causality. J Natl Cancer Inst Monographs 3–13, doi: 10.1093/oxfordjournals.jncimonographs.a003479
Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJF, Meijer CJLM, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518–527, doi: 10.1056/NEJMoa021641
Moreno V, Bosch FX, Muñoz N, Meijer CJLM, Shah KV, Walboomers JMM, Herrero R, Franceschi S, International Agency for Research on Cancer. Multicentric Cervical Cancer Study Group (2002) Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 359: 1085–1092, doi: 10.1016/S0140-6736(02)08150-3
Muñoz N, Franceschi S, Bosetti C, Moreno V, Herrero R, Smith JS, Shah KV, Meijer CJLM, Bosch FX, International Agency for Research on Cancer. Multicentric Cervical Cancer Study Group (2002) Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet 359: 1093–1101, doi: 10.1016/S0140-6736(02)08151-5
Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV (1995) Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 87: 796–802, doi: 10.1093/jnci/87.11.796
Bosch FX, Muñoz N, de Sanjosé S, Izarzugaza I, Gili M, Viladiu P, Tormo MJ, Moreo P, Ascunce N, Gonzalez LC (1992) Risk factors for cervical cancer in Colombia and Spain. Int J Cancer 52: 750–758, doi: 10.1002/ijc.2910520514
Muñoz N, Bosch FX, de Sanjosé S, Tafur L, Izarzugaza I, Gili M, Viladiu P, Navarro C, Martos C, Ascunce N (1992) The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain. Int J Cancer 52: 743–749, doi: 10.1002/ijc.2910520513.